Australia Spinal Cord Stimulation Market Industry Trends and Forecast to 2034: Segmented by (Product, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Australia · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$42.2 MnPlaceholder estimate
Estimate 2025$46.3 Mn1.3% of the global market
Projected 2034$106.6 Mn 130.1%Adds $60.3 Mn over 9 forecast years
CAGR 2025–20349.7%Faster than 45% of 173 Medical Devices markets here
3 in AustraliaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Australia Spinal Cord Stimulation Market Analysis Executive Summary
Spinal cord stimulation sends mild electrical pulses to the spinal cord to block chronic pain signals.
Key segments of the spinal Cord Stimulation market include product (Rechargeable, Non-Rechargeable and Closed-Loop) and indication (Failed Back Surgery, Diabetic Neuropathy and Complex Regional Pain).
Australia Spinal Cord Stimulation market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Australia Spinal Cord Stimulation Market Dynamics
Market Growth Drivers
An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the spinal Cord Stimulation market.
Opportunity
Biomarker-guided treatment, earlier diagnosis and new device-based therapies give the spinal Cord Stimulation market strong room to grow.
Market Restraints
Hard-to-reach brain targets, high failure rates in trials, side effects and high prices for new therapies hold back the spinal Cord Stimulation market.
Competitive Landscape for Spinal Cord Stimulation Market in Australia
The spinal Cord Stimulation market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Spinal Cord Stimulation Market in Australia
Spinal Cord Stimulation in Australia: rules, payment and research
Medical devices must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied.[1] Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.[2] ClinicalTrials.gov lists 3 studies on Spinal Cord Stimulation that are recruiting, active or about to start in Australia.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how spinal Cord Stimulation products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Australia.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Product
4.2 By Indication
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Medtronic
7.2 Boston Scientific
7.3 Abbott Laboratories
7.4 Nevro
7.5 Saluda Medical
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The spinal Cord Stimulation market can be segmented based on various criteria, including product, indication and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: FDA 510(k) and PMA databases, 510(k) clearances and PMA approvals since 2015 for devices whose name has this market's words. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Spinal Cord Stimulation right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Spinal Cord Stimulation in context
Australia compared
Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 15 countries we cover in APAC.[1]
Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 15 countries we cover in APAC.[2]
People aged 65 and over: 18.1% of people (2025). World: 10.4% of people (2025). 3rd highest of the 16 countries we cover in APAC.[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
How big is the Spinal Cord Stimulation market in Australia?
Placeholder estimate: about $46.3 Mn in 2025, rising to about $106.6 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Spinal Cord Stimulation market in Australia growing?
Placeholder estimate: about 9.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Spinal Cord Stimulation market report cover?
The report splits the market by product (Rechargeable, Non-Rechargeable, Closed-Loop), indication (Failed Back Surgery, Diabetic Neuropathy, Complex Regional Pain) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Spinal Cord Stimulation market?
Key players include Medtronic, Boston Scientific Corporation, Abbott Laboratories, Nevro and Saluda Medical.
What is driving the Spinal Cord Stimulation market?
An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the spinal Cord Stimulation market.
Who regulates Spinal Cord Stimulation in Australia?
Medical devices must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied. Source: Therapeutic Goods Administration. Checked 14 Nov 2026.
How is healthcare paid for in Australia?
Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines. Source: Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
How many clinical trials on Spinal Cord Stimulation are running in Australia?
3 studies are recruiting, active or about to start in Australia, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
How much research is published on Spinal Cord Stimulation?
PubMed lists 2,338 papers on Spinal Cord Stimulation added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.